Armonk, N.Y. - 17 Sep 2014: IBM (NYSE: IBM) today announced that Caris Life Sciences is using IBM technical computing and storage technology to accelerate the company’s molecular profiling services for cancer patients. These services deliver critically important information to help oncologists develop tailored therape
utic plans for each patient’s unique cancer, which could lead to better health outcomes and reduced costs to the healthcare system in general.
IBM News room - 2014-09-17 Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection - United States
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.